Olivier Dulac

Olivier Dulac is a prominent inventor based in Paris, France. He has made significant contributions to the field of neuroscience through his innovative work on NMDA receptor modulators. His research focuses on developing compounds that can aid in the treatment of various central nervous system diseases.

Latest Patents

Olivier Dulac holds a patent for NMDA receptor modulators, which includes compositions comprising these compounds and their use in treating diseases involving the central nervous system. The patent specifically addresses compounds of the type 1-(indol-3-yl)-3-hydroxy-3-(2-oxo-2-ethyl)-indol-2-ones. These compounds are intended for use in pharmaceutical compositions aimed at preventing or treating conditions such as severe/resistant epilepsy, cognitive disorders like autism, strokes, schizophrenia, and degenerative diseases including Parkinson's and Alzheimer's diseases. His work also extends to addressing issues related to Rett syndrome, amyotrophic lateral sclerosis, migraine, dementia, and major depressive disorder. Olivier Dulac has 1 patent to his name.

Career Highlights

Olivier is associated with Adpuerivitam, where he continues to advance his research and development efforts. His work is pivotal in the ongoing quest to find effective treatments for complex neurological conditions.

Collaborations

Olivier collaborates with notable colleagues such as Mouad Alami and Jean Daniel Brion, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Olivier Dulac's contributions to the field of NMDA receptor modulation highlight his commitment to advancing medical science. His innovative approach to treating central nervous system diseases positions him as a key figure in the ongoing development of effective therapeutic solutions.

Profile summary based on public USPTO records.